Arrythmias and heart rate increase in the LEADER trial and relation to risk of cardiovascular events

25 August 2018 (00:00 - 00:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Mansoor Husain

University of Toronto, Toronto (Canada)

8 More presentations in this session

Presentation thumbnail

Vascular endothelial growth factor-C and mortality in patients with diabetes and suspected coronary artery disease: from the ANOX study

Doctor T. Unoki (Kumamoto, JP)

Presentation thumbnail

Cardiovascular outcomes associated with SGLT2 vs DPP4 inhibitors in type 2 diabetic patients with and without established cardiovascular diseases: a propensity score-matched study

Professor B. Yan (Hong Kong, CN)

Abstract Slides

Presentation thumbnail

The combined treatment with glucagon like peptide-1 analogues and sodium-glucose co-transporter 2 causes a greater improvement of arterial stiffness than each treatment alone in type 2 diabetes .

Doctor I. Ikonomidis (Athens, GR)

Abstract Slides

Presentation thumbnail

Cardiovascular risk according to add-on therapy in patients with type 2 diabetes

Mr D. Aagaard (Copenhagen, DK)

Presentation thumbnail

Lentiviral transfer of interleukin 4 gene to 3T3-L1 adipocytes prevents development of lipid-induced insulin resistance

Ms S. Michurina (Pavlovo, RU)

Access the full session

Session thumbnail

Poster Session 3 - Diabetes, adiposity and metabolic syndrome

The Event

ESC Congress 2018

25 August - 29 August 2018

You may be interested in

Congress Presentation

Case 1 - a middle-aged male with T2DM: polypharmacy in a primary prevention setting

Congress Presentation

Cardiovascular risk reduction: should we target pre-diabetes?

Webinar

Prevention of heart failure in diabetic patients at population level

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources